Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Munoz

Showing results (101-110 of 169) with videos related to

Pageof 17
Sort By:
Nature Communications|December 11, 2014
Proteome adaptation in cell reprogramming proceeds via distinct transcriptional networksMarco Benevento, Peter D Tonge, Mira C Puri, et al.
Leukemia & Lymphoma|November 3, 2020
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)Morton Coleman, David Belada, René-Olivier Casasnovas, et al.
Operative Neurosurgery (Hagerstown, Md.)|October 13, 2022
Contactless Ultrasonic Cavitation for the Prevention of Shunt Obstruction in Hydrocephalus: A Proof-of-Concept StudyEmilio Gomez-Gonzalez, Francisco Javier Munoz-Gonzalez, Alejandro Barriga-Rivera, et al.
Transplantation and Cellular Therapy|October 27, 2023
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisCaron A Jacobson, Javier Munoz, Fang Sun, et al.
Nature Communications|May 25, 2023
Decoding protein methylation function with thermal stability analysisCristina Sayago, Jana Sánchez-Wandelmer, Fernando García, et al.
Blood|July 24, 2019
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCLAndre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, et al.
Journal of Hematology & Oncology|August 16, 2024
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphomaAllison Rosenthal, Javier Munoz, Monika Jun, et al.
Haematologica|June 19, 2025
Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patientsSuheil Albert Atallah-Yunes, Matthew J Rees, Thomas M Habermann, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trialsMehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
Pageof 17

Showing results (101-110 of 169) with videos related to

Sort By:
Pageof 17
Nature Communications|December 11, 2014
Proteome adaptation in cell reprogramming proceeds via distinct transcriptional networksMarco Benevento, Peter D Tonge, Mira C Puri, et al.
Leukemia & Lymphoma|November 3, 2020
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)Morton Coleman, David Belada, René-Olivier Casasnovas, et al.
Operative Neurosurgery (Hagerstown, Md.)|October 13, 2022
Contactless Ultrasonic Cavitation for the Prevention of Shunt Obstruction in Hydrocephalus: A Proof-of-Concept StudyEmilio Gomez-Gonzalez, Francisco Javier Munoz-Gonzalez, Alejandro Barriga-Rivera, et al.
Transplantation and Cellular Therapy|October 27, 2023
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisCaron A Jacobson, Javier Munoz, Fang Sun, et al.
Nature Communications|May 25, 2023
Decoding protein methylation function with thermal stability analysisCristina Sayago, Jana Sánchez-Wandelmer, Fernando García, et al.
Blood|July 24, 2019
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCLAndre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, et al.
Journal of Hematology & Oncology|August 16, 2024
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphomaAllison Rosenthal, Javier Munoz, Monika Jun, et al.
Haematologica|June 19, 2025
Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patientsSuheil Albert Atallah-Yunes, Matthew J Rees, Thomas M Habermann, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trialsMehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
Pageof 17